Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
Ardmore Shipping(US:ASC) Prnewswire·2025-08-13 07:00- The combination of ASC47 low dose with tirzepatide also restored the body composition of obese mice to the level of healthy non-obese mice. At the end of treatment, the percentage of total muscle mass over the total body weight of obese mice treated with the combination of ASC47 low dose with tirzepatide was similar to healthy non-obese mice, 60.4% vs 62.0% respectively. - The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weigh ...